CURE:ARCA-Direxion Daily Healthcare Bull 3X Shares (USD)

ETF | Trading--Leveraged Equity | NYSE Arca

Last Closing

USD 92.3

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, of 300% of the performance of the Health Care Select Sector Index. The fund creates long positions by investing at least 80% of its assets in the securities that comprise the Health Care Select Sector Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. The index is provided by Standard & Poor's and includes domestic companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Inception Date: 15/06/2011

Primary Benchmark: S&P Health Care Select Sector TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.97%

Management Expense Ratio: 1.06 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ 0.95 %

+2.03 (+2.44%)

USD 27.82B
SOXL Direxion Daily Semiconductor B.. 1.10 %

+2.29 (+8.39%)

USD 9.92B
FNGU MicroSectors FANG+ Index 3X Le.. 0.00 %

+27.32 (+4.44%)

USD 7.96B
QLD ProShares Ultra QQQ 0.95 %

+2.03 (+1.82%)

USD 7.84B
SSO ProShares Ultra S&P500 0.90 %

+0.95 (+1.00%)

USD 5.60B
UPRO ProShares UltraPro S&P500 0.92 %

+1.53 (+1.67%)

USD 4.27B
TECL Direxion Daily Technology Bull.. 1.17 %

+2.74 (+2.88%)

USD 3.43B
YINN Direxion Daily FTSE China Bull.. 1.02 %

+0.49 (+1.73%)

USD 1.61B
USD ProShares Ultra Semiconductors 0.95 %

+4.71 (+7.30%)

USD 1.16B
UDOW ProShares UltraPro Dow30 0.95 %

+0.10 (+0.10%)

USD 0.91B

ETFs Containing CURE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.28% 18% F 19% F
Dividend Return 0.94% 39% F 13% F
Total Return -8.33% 18% F 17% F
Trailing 12 Months  
Capital Gain -6.58% 24% F 22% F
Dividend Return 0.97% 39% F 13% F
Total Return -5.61% 22% F 19% F
Trailing 5 Years  
Capital Gain 23.41% 62% D 63% D
Dividend Return 4.84% 79% B- 12% F
Total Return 28.25% 64% D 55% F
Average Annual (5 Year Horizon)  
Capital Gain 19.24% 42% F 80% B-
Dividend Return 19.89% 40% F 78% C+
Total Return 0.64% 55% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 43.63% 81% B- 22% F
Risk Adjusted Return 45.59% 75% C 60% D-
Market Capitalization 0.17B 59% D- 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.